Joint Formulary & PAD

Infliximab - Pouchitis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Associated Icons :
Off Label
SPC
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Infliximab
Indication :
Pouchitis
Group Name :
Keywords :
biosimilar, cytokine modulator, monoclonal antibody, mab, anti-TNF, TNF-alpha, subcutaneous, pre-filled pen, pre-filled syringe, inflammation of the ileal reservoir
Brand Names Include :
Inflectra, Remsima, Flixabi, Zessly
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Drugs

Below are listed other drugs that are used to treat Pouchitis.

Committee Recommendations (1)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve infliximab for chronic pouchitis after treatment with steroids and/or antibiotics in combination.

Infliximab will be assigned a RED traffic light status on the Prescribing Advisory Database (PAD)

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”